

Description

- Through its family of companies, the world's most comprehensive and broadly based manufacturer of health care products
- Serves the Consumer, Pharmaceutical and Medical Devices markets by developing broadly accessible, high quality, innovative products and services that advance the health and well-being of people

Consistent Performance


- 32 consecutive years of earnings increases adjusted for special items¹
- 54 consecutive years of dividends increases²

	One Year ³	Five Years ³	Ten Years ³
Sales	(5.7%)	2.6%	3.3%
Diluted Adjusted Earnings per Share ¹	(3.0%)	5.4%	6.2%
Dividend Growth	6.9%	6.9%	8.8%
Total Return to Shareholders	1.2%	14.2%	8.7%

Broadly Based/Exceptional Financial Strength

- Over 250 operating companies in 60 countries selling products throughout the world (approximately 49% of sales outside of U.S.)
- Sales split among Consumer, Pharmaceutical and Medical Devices business segments
- More than 100 drugs marketed; 46 drugs over \$50 million; 34 drugs over \$100 million; 11 drugs over \$1 billion
- One of two U.S. industrial companies that still commands a Triple A credit rating by both Standard & Poor's and Moody's credit rating agencies
- Generated annual free cash flow⁴ in 2015 of \$15.8 billion

Net Earnings⁽⁵⁾ (as reported) \$U.S. Millions



¹ Non-GAAP, excludes special items. Reconciliation available in corresponding Annual Reports.


² Includes April 2016 dividend increase

³ Compounded Annual Growth Rates

⁴ Non-GAAP financial measure; defined as operating cash flow less capital spending

⁵ Net Earnings attributable to Johnson & Johnson

New Products Introduced in Past 5 Years



2015 Worldwide
Sales \$70.1 Billion


Worldwide Market Leadership

- The most comprehensive Medical Device company
- 5th largest Pharmaceutical company globally
- 6th largest Biotech company globally
- 6th largest Consumer Health Care company globally
- Worldwide Leader in Major Markets:
 - Antithrombotic agents
 - Antipsychotic (Injectables)
 - Baby & Kids Care
 - Biosurgicals
 - Disposable Contact Lenses
 - Electrophysiology diagnostics & catheters
 - Endo-mechanical
 - Endoscopy
 - Hormone antagonists
 - Infection Prevention
 - Oral Rinses
 - Orthopaedics (Trauma/CMF)
 - OTC
 - SGLT2 Inhibitors
 - Sutures
 - Systemic Antipsoriasis products
 - Wound Care
- Approximately 70% of sales are derived from products/businesses that have a #1 or #2 global market share position

Please visit our Home Page on the Internet at <http://www.jnj.com> for requests for **Company Reports**, including the 2015 Annual Report and SEC filings. Questions regarding stock holdings and the **Dividend Reinvestment Plan**, should be directed to: Computershare Trust Company, N.A. Phone (800) 328-9033

Shareholder Return Comparison

\$100 Dollars invested December 31, 2005



This chart provides a comparison of cumulative total shareholder return for an investment in Johnson & Johnson Common Stock as of December 31, 2015 to a similar investment in the identified indices. Assuming dividends were reinvested, a \$100.00 investment in Johnson & Johnson would have grown to \$231.32 as of December 31, 2015. This compares to a value of \$202.41 for the S&P 500 Stock Index, \$279.32 for the S&P Pharmaceutical Index and \$197.28 for the S&P Healthcare Equipment Index.
Source: Bloomberg

Strong Commitment to New Product Development

- \$9.0 billion in Research & Development expense in 2015
- Numerous external alliances and collaborations entered into annually

Well Positioned for Future Growth

- Creating Value through Innovation
 - Robust pipeline of new and innovative products
- Global Reach/Local Focus
 - Broad geographic reach provides ability to rapidly introduce new products in markets around the world
- Excellence in Execution
 - Maintaining high quality products and standards
- Leading with a Purpose
 - Focus on products which increase access, reduce cost and improve the quality of health care

Investor Information

NYSE Symbol: JNJ


For additional information, contact:

Investor Relations Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Voice: (800) 950-5089
Fax: (732) 524-3867

Press releases, including earnings reports, are available via web access: <http://www.jnj.com>


2015 Sales by Geographic Area

\$U.S. Billions



2015 Sales by Segment*

\$U.S. Billions



* The sum of segments do not equal the total due to rounding

Net Trade Sales

\$U.S. Billions

